First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients

Introduction.In the early 2000s, in type 2 diabetes mellitus (T2DM) treatment, a fundamentally new class of drugs appeared—the incretin mimetics. The use of dipeptidyl peptidase-4 (DPP-4) inhibitors allowed the safety of the T2DM therapy to be increased by reducing several parameters, including hypo...

Full description

Saved in:
Bibliographic Details
Main Authors: Karina Oganesovna Galstyan, Liudmila Viktorovna Nedosugova, Nina Alexandrovna Petunina, Julia Alexandrovna Trakhtenberg, Natalia Vadimovna Vostokova, Oksana Vladimirovna Karavaeva, Tatiana Evgenievna Chasovskaya
Format: article
Language:EN
RU
Published: Endocrinology Research Centre 2016
Subjects:
diabetes mellitus type 2
glycated hemoglobin
нbа1с
dpp-4 inhibitor
gosogliptin
vildagliptin
Nutritional diseases. Deficiency diseases
RC620-627
Online Access:https://doaj.org/article/5f62c58ac7554d608a2ddc46a781c7e3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/5f62c58ac7554d608a2ddc46a781c7e3

Similar Items